Glycosylation deficiency of lipopolysaccharide-binding protein and corticosteroid-binding globulin associated with activity and response to treatment for rheumatoid arthritis

Abstract

Background: Serum protein glycosylation is an area of investigation in inflammatory arthritic disorders such as rheumatoid arthritis (RA). Indeed, some studies highlighted abnormalities of protein glycosylation in RA. Considering the numerous types of enzymes, monosaccharides and glycosidic linkages, glycosylation is one of the most complex post translational modifications. By this work, we started with a preliminary screening of glycoproteins in serum from RA patients and controls. Methods:In order to isolate glycoproteins from serum, lectin wheat germ agglutinin was used and quantitative differences between patients and controls were investigated by LC-MS/MS. Consequently, we focused our attention on two glycoproteins found in this explorative phase: corticosteroid-binding globulin (CBG) and lipopolysaccharidebinding protein (LBP). The subsequent validation with immunoassays was widened to a larger number of early RA (ERA) patients (n = 90) and well-matched healthy controls (n = 90). Results:We observed a significant reduction of CBG and LBP glycosylation in ERA patients compared with healthy controls. Further, after 12 months of treatment, glycosylated CBG and LBP levels increased both to values comparable to those of controls. In addition, these changes were correlated with clinical parameters. Conclusions:This study enables to observe that glycosylation changes of CBG and LBP are related to RA disease activity and its response to treatment.

Exchanging dietary fat source with extra virgin olive oil does not prevent progression of diet-induced non-alcoholic fatty liver disease and insulin resistance

“…However, it has been shown that neither LBP nor MyD88 are solely regulated at the level of mRNA expression and also in dependence of different ligands/ compounds (e.g. endotoxin, peptidglycane and proinflammatory cytokines) [67][68][69][70]. Difference between the studies of Cariello et al [62] and our study might have resulted from differences in the composition of the oils used but may also be related to difference in the models (e.g.…”

Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis

“…In addition, current medical practice suggests an increasingly personalised medicine. Thereby, more and more studies, such as ours, are investigating molecules of interest that can guide the therapeutic process, often derived from promising studies in the broad field of rheumatoid arthritis [32][33][34] that could inspire further future studies in JIA. Furthermore, it has recently been shown that sCal can be easily and rapidly detected in blood using a lateral flow immunoassay-based technology, which may provide a useful point-of-care testing.…”

Harnessing the Potential of Exosomal miRNAs: A Breakthrough in Rheumatoid Arthritis Diagnosis and Monitoring

“…Protein markers are subject to intricate regulatory mechanisms, encompassing post-translational modi cations and protein interactions. These complexities render their precise and sensitive detection and quanti cation challenging, particularly in the initial phases of a disease [31,32]. On the contrary, RNA markers can detect early changes in cells or tissues and are often more reversible, rendering them advantageous for assessing treatment e cacy and monitoring disease progression [33].…”